scholarly article | Q13442814 |
P50 | author | Danning Li | Q89267923 |
P2093 | author name string | Qin Su | |
Guangping Gao | |||
Jean King | |||
Julio Sanmiguel | |||
Reuben Matalon | |||
Hongxia Xu | |||
Dominic J Gessler | |||
Constance Moore | |||
Serafettin Tuncer | |||
P2860 | cites work | WHAT DOES fMRI TELL US ABOUT NEURONAL ACTIVITY? | Q22121987 |
Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease | Q24321556 | ||
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy | Q24535690 | ||
Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease | Q24605407 | ||
Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease | Q27339223 | ||
Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination | Q28571447 | ||
The basis of anisotropic water diffusion in the nervous system - a technical review | Q29616528 | ||
Mapping resting-state brain networks in conscious animals. | Q30475142 | ||
A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice. | Q30559496 | ||
Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system | Q30885534 | ||
Dissection of hippocampal dentate gyrus from adult mouse. | Q30890249 | ||
N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology | Q33271816 | ||
Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings | Q33855213 | ||
Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10 | Q33870720 | ||
Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. | Q33933163 | ||
Gata6 regulates aspartoacylase expression in resident peritoneal macrophages and controls their survival | Q33964290 | ||
Molecular analysis of vector genome structures after liver transduction by conventional and self-complementary adeno-associated viral serotype vectors in murine and nonhuman primate models | Q34123269 | ||
Long-term follow-up after gene therapy for canavan disease. | Q34318553 | ||
Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. | Q34659417 | ||
Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. | Q34664932 | ||
Uncovering intrinsic connectional architecture of functional networks in awake rat brain | Q34774789 | ||
Self-complementary AAV vectors; advances and applications | Q34804660 | ||
Adeno-associated viruses undergo substantial evolution in primates during natural infections | Q35022838 | ||
Alteration of brain default network in subacute phase of injury in concussed individuals: resting-state fMRI study | Q35380783 | ||
Resting State Functional Connectivity in Mild Traumatic Brain Injury at the Acute Stage: Independent Component and Seed-Based Analyses | Q35857349 | ||
A Single Injection of Recombinant Adeno-Associated Virus into the Lumbar Cistern Delivers Transgene Expression Throughout the Whole Spinal Cord. | Q36352399 | ||
Investigation into the role of N-acetylaspartate in cerebral osmoregulation | Q36708837 | ||
N-acetylaspartate catabolism determines cytosolic acetyl-CoA levels and histone acetylation in brown adipocytes | Q36764814 | ||
rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System. | Q37043518 | ||
Mapping thalamocortical networks in rat brain using resting-state functional connectivity | Q37274965 | ||
Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? | Q37423187 | ||
N-acetylaspartate (NAA) induces neuronal differentiation of SH-SY5Y neuroblastoma cell line and sensitizes it to chemotherapeutic agents | Q38781562 | ||
Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. | Q38831889 | ||
Absence of SHATI/Nat8l reduces social interaction in mice. | Q39287252 | ||
Spongy degeneration of the central nervous system (Van Bogaert and Bertrand type; Canavan's disease)A review | Q39938567 | ||
Characterization of astrocyte-specific conditional knockouts | Q40141365 | ||
N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. | Q40382537 | ||
CT and MR imaging of Canavan disease | Q42052033 | ||
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes | Q42739394 | ||
Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model | Q43291024 | ||
Resting state fMRI reveals increased subthalamic nucleus-motor cortex connectivity in Parkinson's disease. | Q43912490 | ||
Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease | Q44054737 | ||
Metabolic changes in the knockout mouse for Canavan's disease: implications for patients with Canavan's disease | Q44627482 | ||
Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. | Q44719583 | ||
Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease | Q45090529 | ||
In vivo quantitation of cerebral metabolite concentrations using natural abundance 13C MRS at 1.5 T. | Q45297254 | ||
Variable course of Canavan disease in two boys with early infantile aspartoacylase deficiency | Q45749661 | ||
Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model. | Q45934574 | ||
Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain | Q46588627 | ||
Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with canavan disease | Q48115232 | ||
Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia | Q48165321 | ||
Automatic quantitation of localized in vivo 1H spectra with LCModel | Q48842365 | ||
N-Acetyl-L-aspartic acid in brain. | Q51332544 | ||
The clinical course of Canavan disease. | Q51994919 | ||
Glial Glycolysis Is Essential for Neuronal Survival in Drosophila. | Q52812695 | ||
Magnetic resonance imaging in juvenile Canavan disease | Q61735501 | ||
Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes | Q73484896 | ||
P4510 | describes a project that uses | ImageJ | Q1659584 |
P433 | issue | 3 | |
P921 | main subject | myelination | Q14876135 |
P304 | page(s) | e90807 | |
P577 | publication date | 2017-02-09 | |
P1433 | published in | JCI insight | Q27727187 |
P1476 | title | Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease | |
P478 | volume | 2 |
Q54210504 | A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. |
Q64040883 | Adeno-associated virus vector as a platform for gene therapy delivery |
Q49886923 | Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model |
Q64977765 | Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. |
Q33753200 | Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease. |
Q64040426 | Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System |
Q90220036 | Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders |
Q90395032 | Pathophysiology and Treatment of Canavan Disease |
Q91707074 | Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? |
Q50751527 | Rescuing Canavan disease: engineering the wrong cell at the right time |
Q45874163 | Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy |